18
Participants
Start Date
August 16, 2018
Primary Completion Date
September 13, 2018
Study Completion Date
September 13, 2018
Milademetan Treatment A
Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions
Milademetan Treatment B
Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
Milademetan Treatment C
Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.
Covance Clinical Research Unit, Inc., Dallas
Lead Sponsor
Daiichi Sankyo
INDUSTRY